You are here
Early risk assessment of moderate to severe acute kidney injury
Used in the acutely ill, the NEPHROCHECK® test helps clinicians identify kidney stress early, allowing them to confirm or optimize their treatment strategy while mitigating the risk of acute kidney injury for the acutely ill.
- Early “alarm system” specific to kidney stress, before damage occurs
- High sensitivity and negative predictive value
- Time to Result < 1 hour
In intensive care units, critically ill patients are commonly exposed to nephrotoxic drugs (such as antibiotics, vasopressors, diuretics and radiocontrast agents) that help preserve their key vital functions but can cause serious complications, up to permanent kidney loss. Acute Kidney Injury (AKI) occurs in more than 50% of patients on day 1 of their stay1. It is associated with a 10-fold increase in hospital mortality rates2, while hospital costs, length of stay and 30-day re-admissions can become at least twice as severe3,4.
AKI is a silent killer, with no immediate specific signs or symptoms. Diagnosis with commonly used kidney function tests often comes too late6. The good news is that both acute and long-term kidney damage can be avoided if the risk is identified and managed early.5 What if you had an opportunity to intervene proactively and preserve your patient’s renal function?
NEPHROCHECK® is an innovative test that detects kidney stress prior to actual damage, when intervention can still make a difference. It is intended to be used as a risk assessment test, in conjunction with clinical evaluation, to aid in identifying patients at risk for developing moderate or severe AKI within 12 hours.
With this early warning, intensivists may either rule out patient with confidence, or implement a series of nephroprotective measures to significantly improve patient outcomes and reduce costs7,8, avoiding the need for dialysis and other comorbidities that typically result from AKI.
See how NEPHROCHECK® can make a difference
Part 1 - Meet Mary
Part 2 - Meet Mary
The kidneys’ alarm system
The NEPHROCHECK® test detects TIMP-2 (tissue inhibitor of metalloproteinases-2) and IGFBP-7 (insulin-like growth factor-binding protein 7).
These novel urinary biomarkers are produced by stressed kidney cells as an early warning signal, before the onset of acute kidney injury.
Specific to kidney stress, they are not affected by any of the usual co-morbidities (such as sepsis, trauma, chronic kidney disease or cancer).9
The NEPHROCHECK® test provides a single quantitative result, the AKIRISK™ score.
What does it mean?
Want to know more about how NEPHROCHECK® may help you reach your ultimate goal, to save patients, while limiting potential additional harm to their kidneys?
Get contacted by a bioMérieux representative ➔
1. Hoste EAJ, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Medecine 2015;41:1411–1423.
2. Hobson C, et al. Cost and mortality associated with postoperative acute kidney injury. Ann Surg. 2014;00:1-8.)
3. Dasta JF, et al. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant. 2008;23(6):1970-1974.
4. Brown JR, et al, for the Northern New England, Cardiovascular Disease Study Group. Impact of perioperative acute kidney injury as a severity index for thirty-day readmission after cardiac surgery. Ann Thorac Surg. 2014;97(1):111-117.
5. Mehta RL, et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015.
6. McCullough PA, et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol. 2013;182:13-29.
7. Göcze I, et al. Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigpAK Study. Ann Surg. Published online August 2017.
8. Meersch M, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017 Jan 21.
9. Kashani K et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Critical Care 2013 Feb 6;17(1):R25.
10. KDIGO Clinical Practice Guideline for Acute Kidney Injury, http://www.kidney-international.org
- Engelman DT, et al. Guidelines for Perioperative Care in Cardiac Surgery: Enhanced Recovery After Surgery Society Recommendations. JAMA Surg. 2019;154(8):755–766.
- Nadim MK, et al. Cardiac and Vascular Surgery-Associated Acute Kidney Injury: The 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group. J Am Heart Assoc. 2018 Jun 5; 7(11): e008834.
- KDIGO Clinical Practice Guideline for Acute Kidney Injury
- Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement - PubMed (nih.gov)
Technical specifications for VIDAS® NEPHROCHECK®
|References||421172-03 (EU IVD)
421172-01 (FDA Cleared)
|Tests / kit||30 (EU IVD)
60 (FDA cleared - US)
|Sample volume||100 uL|
|Time to Result||46 minutes|
|AKIRISK™ Score measuring range||0.04 - 10.00|
|Calibration & Control frequency||Every 56 days|
Not all of the products are FDA cleared.
FDA cleared products may not be cleared for all indications mentioned on this site.
Product claims may differ from country to country on regulations and approvals. Please contact your country representative for further details.
Please consult your local bioMérieux representative for product availability in your country
- Legal Notice
- Copyright 2022 bioMérieux SA